Over the past six months (April 2026 - October 2026), Xeris Biopharma's stock experienced several notable events. On September 29, 2026, the stock surged 6% following reports of a potential acquisition by H Lundbeck, despite the company's denial. Inducement grants were announced for 60 new employees on October 1, 2026, and the CFO sold 5,000 shares on October 2, 2026. The company hosted a webinar on September 9, 2026, detailing its XP-8121 development program and presented at the H.C. Wainwright Global Investment Conference on September 14, 2026, highlighting revenue growth and pipeline potential. Second Quarter 2026 financial results, reported on August 6, 2026, showed a 34% year-over-year increase in net product revenue, an 81% increase in Recorlev sales, and raised full-year revenue guidance, though it included a loss on convertible notes extinguishment. Xeris participated in the Jefferies Global Healthcare Conference on June 3, 2026. First Quarter 2026 results, reported on May 7, 2026, indicated a 43% year-over-year increase in total product revenue and a 95% increase in Recorlev net revenue. The stock price increased by 68.71% over the last six months and 22.77% over the last year, with a 24.60% increase between October 6, 2025, and October 5, 2026. The 52-week range was between $5.25 and $11.33. Analyst ratings are largely positive, with six buy ratings and one hold rating, and an average target price of $12.86, suggesting a potential upside of 26.17%. Insider selling totaled $4.8 million in the past year, with no insider buying.
